The US and Drug Administration (FDA) this week convened a panel of outside experts to weigh in on the readiness of a first-of-its-kind cancer therapy. The treatment, which works by tweaking a patient’s own cells, is a type of immunotherapy called CAR T-cell therapy and has been in clinical trials for several years. One drug maker is now seeking FDA approval to use the treatment in pediatric and young adult patients ages 3 to 25 with B-cell acute lymphoblastic leukemia (ALL) that has not responded to standard care.
After the July 12 day-long meeting, the FDA panel unanimously recommended that the agency approve the treatment. But what does this mean for patients? And is CAR T-cell therapy going to play an increasing role in cancer treatment in general? In this interview, Leonard Lichtenfeld, MD, MACP, American Cancer Society deputy chief medical officer, gives us his take.
Read more Click Here
After the July 12 day-long meeting, the FDA panel unanimously recommended that the agency approve the treatment. But what does this mean for patients? And is CAR T-cell therapy going to play an increasing role in cancer treatment in general? In this interview, Leonard Lichtenfeld, MD, MACP, American Cancer Society deputy chief medical officer, gives us his take.
Read more Click Here
RSS Feed
